Some clusters of children with a multisystem inflammatory syndrome associated with SARS-CoV-2 infection (MIS-C) have been reported. We describe the epidemiological and clinical features of children with MIS-C in Spain. MIS-C is a potentially severe condition that presents in children with recent SARS-CoV-2 infection.
Fever without source (FWS) in infants is a frequent cause of consultation at the emergency department and the emergence of SARS-CoV-2 could affect the approach to those infants. The aim of this study is to define the clinical characteristics and rates of bacterial coinfections of infants < 90 days with FWS as the first manifestation of SARS-CoV-2 infection. This is a cross-sectional study of infants under 90 days of age with FWS and positive SARS-CoV2 PCR in nasopharyngeal swab/aspirate, attended at the emergency departments of 49 Spanish hospitals (EPICO-AEP cohort) from March 1st to June 26th, 2020. Three hundred and thirty-three children with COVID-19 were included in EPICO-AEP. A total of 67/336 (20%) were infants less than 90 days old, and 27/67(40%) presented with FWS. Blood cultures were performed in 24/27(89%) and were negative in all but one (4%) who presented a Streptococcus mitis bacteremia. Urine culture was performed in 26/27(97%) children and was negative in all, except in two (7%) patients. Lumbar puncture was performed in 6/27(22%) cases, with no growth of bacteria. Two children had bacterial coinfections: 1 had UTI and bacteremia, and 1 had UTI. C-reactive was protein over 20 mg/L in two children (one with bacterial coinfection), and procalcitonin was normal in all. One child was admitted to the Pediatric Intensive Care Unit because of apnea episodes. No patients died. Conclusion: FWS was frequent in infants under 90 days of age with SARS-CoV-2 infection. Standardized markers to rule out bacterial infections remain useful in this population, and the outcome is generally good.
Pneumonia is a frequent manifestation of COVID-19 in hospitalized
children. Methods The study involved 80 hospitals in the SARS-CoV-2
Spanish Pediatric National Cohort. Participants were children
<18 years, hospitalized with SARS-CoV-2 community-acquired
pneumonia (CAP). We compared the clinical characteristics of
SARS-CoV-2-associated CAP with CAP due to other viral etiologies from
2012 to 2019. Results In total, 151 children with SARS-CoV-2-associated
CAP and 138 with other viral CAP included. Main clinical features of
SARS-CoV-2-associated CAP were cough 117/151(77%), fever 115/151(76%)
and dyspnea 63/151(46%); 22/151(15%) patients were admitted to a
pediatric intensive care unit (PICU), and 5/151(3%) patients died.
Lymphopenia was found in 63/147(43%) patients. Chest X-ray revealed
condensation (64/151[42%]) and other infiltrates
(87/151[58%]). Compared with CAP from other viral pathogens,
COVID-19 patients were older (8 vs.1 year; odds ratio [OR] 1.42
[95% confidence interval, CI 1.23;1.42]), with lower CRP levels (23
vs.48 mg/L; OR 1 [95%CI 0.99;1]), less wheezing (17 vs.53%; OR
0.18 [95%CI 0.11;0.31]) and greater need of mechanical ventilation,
MV (7 vs.0.7%, OR 10.8 [95%CI 1.3;85). Patients with
non-SARS-CoV-2-associated CAP had a greater need for oxygen therapy (77
vs.44%, OR 0.24 [95%CI 0.14;0.40]). There were no differences in
the use of CPAP or HVF or PICU admission between groups. Conclusion
SARS-CoV-2-associated CAP in children presents differently to other
virus-associated CAP: children are older and rarely have wheezing or
high CRP levels; they need less oxygen but more CPAP or MV. However,
several features overlap, and differentiating the etiology may be
difficult. The overall prognosis is good.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.